🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Breast Cancer Recurrent

Palbociclib and Pembrolizumab In Central Nervous System Metastases NCT02896335Phase 22 sites📍 Boston📍 Boston Massachusetts General Hospital · Tests: Palbociclib, Pembrolizumab A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs NCT06908928Phase 17 sites📍 Duarte📍 La Jolla📍 Aurora Mabwell (Shanghai) Bioscience Co., Ltd. · Tests: bulumtatug fuvedotin, bulumtatug fuvedotin A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer NCT06732323Phase 31 site📍 Beijing Qilu Pharmaceutical Co., Ltd. · Tests: ESG401, Investigator's Choice Chemotherapy YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer NCT07461454Phase 31 site📍 Shanghai MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL202, Eribulin, Capecitabine, Gemcitabine, Vinorelbine Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF NCT03604315Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Computed Tomography, Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 Fluorthanatrace, Positron Emission Tomogr… Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC NCT05464082Phase 21 site📍 Salt Lake City University of Utah · Tests: Functional Precision Oncology A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers NCT07545122Phase 16 sites📍 Wahroonga📍 Westmead📍 Gold Coast Context Therapeutics Inc. · Tests: CT-202 Postoperative Re-irradiaTion With and Without HYPERthermia, or Surgery Only: Toxicity, Quality of Life and Survival in Patients With Locoregional Recurrent Breast Cancer NCT06452485n/a1 site📍 Amsterdam Amsterdam UMC, location VUmc · Tests: No interventions, patient-reported outcomes (PROMs) and toxicity will be collected in both groups. A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) NCT06926868Phase 2, Phase 3295 sites📍 Hot Springs📍 Cerritos📍 Cerritos Bristol-Myers Squibb · Tests: Iza-bren, Nab-paclitaxel, Paclitaxel, Capecitabine, Carboplatin Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy NCT05866458n/a27 sites📍 Cudgen📍 Liverpool📍 North Sydney Ontario Clinical Oncology Group (OCOG) Triple Negative Breast Cancer and Celecoxib. Pilot Study NCT07104266Phase 21 site📍 Sherbrooke Université de Sherbrooke · Tests: Celecoxib (Celebrex), Placebo NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer NCT05704829Phase 244 sites📍 Baden-Baden📍 Freiburg im Breisgau📍 Tübingen Women's Cancer Study Group GmbH · Tests: Trastuzumab deruxtecan, Standard-of-Care Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors NCT04119024Phase 13 sites📍 Duarte📍 Los Angeles📍 Stanford Anusha Kalbasi · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine Phosphate A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases NCT04899908Phase 22 sites📍 Boston📍 Boston Brigham and Women's Hospital · Tests: Stereotactic Radiation, AGuIX gadolinium-based nanoparticles, Placebo Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer NCT02926690Phase 18 sites📍 Norwalk📍 Atlanta📍 Honolulu OncoTherapy Science, Inc. · Tests: OTS167PO Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer NCT05530057Phase 21 site📍 Seoul Seoul National University Hospital · Tests: Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar), Eribulin Mesylate Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) NCT04434040Phase 27 sites📍 San Francisco📍 Chicago📍 New Lenox Dana-Farber Cancer Institute · Tests: Atezolizumab, Sacituzumab govitecan Circulating Tumor DNA NCT06923527Phase 27 sites📍 New Haven📍 Washington D.C.📍 Baltimore Yale University · Tests: Elacestrant Preoperative Partial Breast Reirradiation and Repeat Breast-conserving Surgery in Patients With Recurrent Breast Cancer: the REPEAT Trial NCT06640881Phase 21 site📍 Amsterdam Amsterdam UMC, location VUmc · Tests: ablative single-dose PBI Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence NCT06430541Phase 12 sites📍 Aurora📍 Aurora University of Colorado, Denver · Tests: Psilocybin Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer NCT06367088Phase 21 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: Cadonilimab A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a2 sites📍 Sioux Falls📍 Sydney Sanford Health A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer NCT06471205Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, PD-1 Monoclonal Antibody Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642n/a3 sites📍 Phoenix📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Tissue Collection Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor NCT05933395Phase 21 site📍 Lebanon Dartmouth-Hitchcock Medical Center · Tests: Fulvestrant, Neratinib, Alpelisib, Everolimus, Abemaciclib SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells NCT04150042Phase 12 sites📍 Boston📍 New York General Oncology, Inc. · Tests: Melphalan, BCNU, Vitamin B12B, Vitamin C, Autologous Hematopoietic Stem Cells A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites📍 Los Angeles📍 Tamarac📍 Canton OncoNano Medicine, Inc. · Tests: ONM-501, Cemiplimab Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy NCT04476485n/a12 sites📍 Harbin📍 Changchun📍 Dalian Shengjing Hospital · Tests: endocrine therapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy